Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice.

[1]  J. Kaur,et al.  A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Eugene Y. Kim,et al.  The Novel Cytokine p43 Induces IL-12 Production in Macrophages via NF-κB Activation, Leading to Enhanced IFN-γ Production in CD4+ T Cells1 , 2006, The Journal of Immunology.

[3]  R. Pandey,et al.  Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. , 2005, Tuberculosis.

[4]  J. Buer,et al.  Common and Unique Gene Expression Signatures of Human Macrophages in Response to Four Strains of Mycobacterium avium That Differ in Their Growth and Persistence Characteristics , 2005, Infection and Immunity.

[5]  R. Pandey,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.

[6]  W. Britton,et al.  T cell‐derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection , 2004, Clinical and experimental immunology.

[7]  Anthony J. Hickey,et al.  Pharmaceutical Inhalation Aerosol Technology , 2003 .

[8]  M. Rojas,et al.  Modulation of macrophage apoptosis by antimycobacterial therapy: physiological role of apoptosis in the control of Mycobacterium tuberculosis. , 2003, Toxicology and applied pharmacology.

[9]  S. Kunkel,et al.  Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation. , 2003, American journal of respiratory cell and molecular biology.

[10]  J. Gollob,et al.  IL-12 Induces Monocyte IL-18 Binding Protein Expression Via IFN-γ1 , 2002, The Journal of Immunology.

[11]  B. Gander,et al.  In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  C. Newcomer,et al.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis. , 2001, The Journal of antimicrobial chemotherapy.

[13]  C. Newcomer,et al.  Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model , 2001, Pharmaceutical Research.

[14]  P. Ghazal,et al.  Hijacking and exploitation of IL-10 by intracellular pathogens. , 2001, Trends in microbiology.

[15]  M. Cynamon,et al.  High-Dose Isoniazid Therapy for Isoniazid-Resistant Murine Mycobacterium tuberculosis Infection , 1999, Antimicrobial Agents and Chemotherapy.

[16]  J. Wang,et al.  Macrophages are a significant source of type 1 cytokines during mycobacterial infection. , 1999, The Journal of clinical investigation.

[17]  Z. Toossi,et al.  Regulation of Interleukin-12 by Interleukin-10, Transforming Growth Factor-β, Tumor Necrosis Factor-α, and Interferon-γ in Human Monocytes Infected with Mycobacterium tuberculosis H37Ra , 1998 .

[18]  Q. Myrvik,et al.  Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice , 1997, Infection and immunity.

[19]  R. Young,et al.  T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. , 1997, Journal of immunology.

[20]  J. Flynn,et al.  Role of Tl and T2 Cytokines in the Response to Mycobacterium tuberculosis , 1996, Annals of the New York Academy of Sciences.

[21]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[22]  Eugene Y. Kim,et al.  The novel cytokine p43 induces IL-12 production in macrophages via NF-kappaB activation, leading to enhanced IFN-gamma production in CD4+ T cells. , 2006, Journal of immunology.

[23]  E. Capoluongo,et al.  Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  G. Benard,et al.  Monocyte cytokine secretion in patients with pulmonary tuberculosis differs from that of healthy infected subjects and correlates with clinical manifestations. , 2004, Microbes and infection.

[25]  J. Buer,et al.  Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. , 2004, Tuberculosis.

[26]  Z. Toossi,et al.  Regulation of interleukin-12 by interleukin-10, transforming growth factor-beta, tumor necrosis factor-alpha, and interferon-gamma in human monocytes infected with Mycobacterium tuberculosis H37Ra. , 1998, The Journal of infectious diseases.

[27]  I. Gonda,et al.  Targeting by deposition , 1992 .